Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival
Nina N. Sanford(Southwestern Medical Center), Theodore S. Hong(Massachusetts General Hospital), Thomas F. DeLaney(Massachusetts General Hospital), Eugene J. Koay(The University of Texas MD Anderson Cancer Center), Motaz Qadan(Massachusetts General Hospital), Kenneth K. Tanabe(Harvard University), Lipika Goyal(Stanford Medicine), Cristina R. Ferrone(Cedars-Sinai Medical Center), David P. Ryan(East Carolina University), Clemens Grassberger(University of Washington), Jennifer Y. Wo(Massachusetts General Hospital), B. Noe(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Jill N. Allen(Harvard University), Beow Y. Yeap(Harvard University), Christine E. Eyler(Duke University), J. Pursley(Mayo Clinic), Christopher H. Crane(Memorial Sloan Kettering Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
January 25, 2019
Cited by 147
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k